of the mechanisms and sequence of events that result in vaccine-induced GBS.
The committee encourages active and aggressive follow-up of the reports to passive surveillance system of death in association with immunization. This follow-up should be timely and might include elements such as medical records, laboratory tests, and autopsy results. See the section on General Surveillance and Epidemiologic Studies for elaboration.
The committee was able to identify little information pertaining to the risk of serious adverse events following administration of multiple vaccines simultaneously. This is an issue of increasing concern as more vaccines and vaccine combinations are developed for routine use. Both pre- and postmarketing research should address the issue.
The committee was able to identify little information pertaining to why some individuals react adversely to vaccines when most do not. When it is clear that a vaccine can cause a specific adverse event, research should be encouraged to elucidate the factors that put certain people at risk for that adverse reaction.
Postmarketing surveillance of licensed vaccines in the United States depends upon voluntary reporting. Large numbers of alleged adverse events are reported to the Vaccine Adverse Event Reporting System (VAERS) of the Centers for Disease Control and Prevention and the U.S. Food and Drug Administration. The committee found, however, that follow-up of serious adverse events was often incomplete, and the reported event was often not confirmed because of insufficient clinical, laboratory, or pathologic data. The committee suggests that, in the least, research should be conducted on the performance of passive reporting systems like VAERS. What is the quality and completeness of the information supplied? Can the reports received be used to estimate the true risk of vaccine-induced adverse events? Perhaps most important, how well does the surveillance system detect new